SOPHiA GENETICS (NASDAQ:SOPH) Insider Philippe Menu Sells 5,000 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Philippe Menu sold 5,000 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $7.52, for a total transaction of $37,600.00. Following the completion of the transaction, the insider directly owned 218,387 shares in the company, valued at $1,642,270.24. The trade was a 2.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Philippe Menu also recently made the following trade(s):

• On Monday, July 27th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.66, for a total transaction of $28,300.00.
• On Monday, July 13th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total transaction of $28,500.00.
• On Monday, July 6th, Philippe Menu sold 7,393 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.16, for a total transaction of $38,147.88.
• On Thursday, June 25th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.50, for a total transaction of $27,500.00.
• On Tuesday, May 26th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.95, for a total transaction of $24,750.00.

SOPHiA GENETICS Trading Down 1.6%

Shares of NASDAQ:SOPH opened at $7.50 on Friday. SOPHiA GENETICS SA has a 12-month low of $3.10 and a 12-month high of $7.88. The stock has a market cap of $629.17 million, a PE ratio of -6.52 and a beta of 0.96. The business has a 50 day moving average of $5.89 and a 200-day moving average of $5.23. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The firm had revenue of $23.31 million for the quarter, compared to the consensus estimate of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. As a group, equities research analysts forecast that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. BTIG Research raised their price target on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Finally, HC Wainwright lifted their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, SOPHiA GENETICS presently has a consensus rating of “Hold” and a consensus target price of $10.00.

Institutional Trading of SOPHiA GENETICS

Institutional investors have recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of SOPHiA GENETICS by 246.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after purchasing an additional 5,432,871 shares in the last quarter. AWM Investment Company Inc. acquired a new position in SOPHiA GENETICS in the second quarter valued at about $9,809,000. Akre Capital Management LLC lifted its position in SOPHiA GENETICS by 66.2% during the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after purchasing an additional 1,481,636 shares during the period. Hodges Capital Management Inc. bought a new stake in SOPHiA GENETICS during the first quarter worth about $2,157,000. Finally, Royce & Associates LP bought a new stake in SOPHiA GENETICS during the fourth quarter worth about $2,009,000. 31.59% of the stock is currently owned by institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.